NCT06851611

The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus

An Open Short-term Clinical Pilot Trial on Safety and Immunogenicity of Nasal COVID-19 Vaccine at Different Dose Levels and Administration Methods

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Rokote Laboratories Finland Oy · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5 adenoviral vector producing the SARS-CoV-2 spike protein. In this trial, the primary comparison in terms of safety and immunogenicity will be between two different dose levels of COV2 booster vaccine (low, high), and two different administration methods (nasal drops, nasal spray). In addition, COV2 vaccine will also be evaluated in vaccine naive subjects.

Conditions

• COVID19, Sars-Cov-2

Interventions

Type	Name	Description
BIOLOGICAL	COVID-19 vaccine, low dose level	Test article
BIOLOGICAL	COVID-19 vaccine, high dose level	Test article
OTHER	Nasal Drops	Method of administration of test article
OTHER	Nasal Spray	Method of administration of test article

Timeline

• Start date: 2025-01-21
• Primary completion: 2025-06-25
• Completion: 2025-06-26
• First posted: 2025-02-28
• Last updated: 2025-12-08

Locations

1 site across 1 country: Finland